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pidemiology of Multiple-Resistant Gram-Negative Bacte-
ia in Europe and North America
. Srinivasan
Division of Healthcare Quality Promotion, CDC, Atlanta,
A, USA
ackground: Recent reports of multidrug resistant (MDR)
ram-negative rods (GNR) are concerning; however, it is not
lear how extensive this problem is nationally. The National
ealthcare Safety Network (NHSN) collects information on
elect hospital-associated infections (HAI) from about 600
ospitals throughout the U.S. and is a system that may be
sed to evaluate this problem.
Objectives: To describe the prevalence of MDR among K.
neumoniae, P. aeruginosa or A. baumannii HAIs reported to
HSN.
Methods: HAIs due to the aforementioned pathogens
eported to the NHSN device or procedure modules from
anuary 1, 2006 to September 15, 2007 were evaluated.
solates were included if they had susceptibility results for
t least 1 agent in each of 4 classes of antimicrobials:
minoglycosides, quinolones, beta-lactams (penicillins and
ephalosporins), and carbapenems. Isolates were classiﬁed
s MDR if reported as resistant or intermediate to all drugs
ested in all 4 classes. Other potentially important resis-
ance phenotypes were also evaluated. Pooled mean (%)
DR were determined by pathogen and HAI type. To better
haracterize the national prevalence, results were strati-
ed to control for facilities that reported large numbers of
DR-GNR (outlier facilities).
Results: Overall, 313 hospitals in 42 states reported 4,790
ospital-associated infections with selected GNR: 2,432 P.
eruginosa (bloodstream infection [BSI] 327, ventilator asso-
iated pneumonia [VAP] 889, urinary tract infection [UTI]
66, surgical site infection [SSI] 350); 1,740K. pneumonia
BSI 490, VAP 417, UTI 650, SSI 183); and 791 A. bauman-
ii (BSI 221, VAP 439, UTI 92, SSI 39). Among P. aeruginosa,
% of isolates were MDR and 6% were non-susceptible (NS) to
oth quinolones and aminoglycosides, agents often added to
eta-lactams to treat Pseudomonas. Among K. pneumoniae,
% of isolates were MDR and 10% were NS to carbepen-
ms. Among A. baumannii, 26% were MDR. MDR isolates
ere reported from 68 (30%) facilities in 21 states and
ere more commonly reported from larger hospitals (>500
eds, p < 0.001). The percent isolates that were MDR varied
lightly by type of HAI (table). Pooled mean (%) MDR varied
hen states with outlier facilities were excluded (table).
Conclusions: As deﬁned, MDR among GNR is not rare in US
ospitals reporting data to NHSN. MDR-GNR were not con-
ned to one geographic region and are more common, but
ot limited to, larger hospitals. The paucity of novel antimi-
robial agents in development to treat these organism places
ncreasing emphasis on infection control efforts.
oi:10.1016/j.ijid.2008.05.060
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urden and Future Gram-Negative Resistance in
sia/Australia
.L. Paterson
University of Queensland, Brisbane, Australia
esistance of Gram negative bacilli to commonly used
ntibiotics is commonplace in the Asia-Paciﬁc region. In
eneral, rates of resistance are highest in India and
ome parts of China and lowest in Australia and New
ealand. Extended-spectrum beta-lactamase (ESBL) produc-
ng Klebsiella pneumoniae and Enterobacter cloacae are
igniﬁcant nosocomial pathogens in the region. Rates of
SBL production in some species is as high as 80% in some
nstitutions. Community-onset ESBL producing Escherichia
oli is becoming evident in certain geographic regions such
s Thailand, India and some parts of Australia. CTX-M-
5 has been described in this scenario in India. There
re reports of KPC-producing organisms in China, but thus
ar this resistance mechanism has not been described
lsewhere in Asia/Paciﬁc. Metallo-beta-lactamase produc-
ng Pseudomonas aeruginosa, Acinetobacter baumannii and
nterobacteriaceae are well described in the Asia-Paciﬁc
egion. Carbapenem resistant A. baumannii is a particularly
roblematic pathogen in some ICUs. Signiﬁcant issues with
egards to the high prevalence of antibiotic resistant Gram
egative bacteria in the region include over the counter
vailability of antibiotics in some countries, agricultural use
f antibiotics and suboptimal infection control. Attention to
hese issues is essential to forestall the onset and spread of
olymyxin resistance in the region.
oi:10.1016/j.ijid.2008.05.061
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ow to Prevent the Spread of Multiple-Resistant Gram-
egative Bacteria in the Hospital Setting
. Harbarth
Geneva University Hospitals, Geneva, Switzerland
nfections caused by multi-resistant Gram-negative bac-
eria are thought to cause increased morbidity, longer
ength of hospital stay, and higher treatment costs when
ompared to infections caused by susceptible strains. Suc-
essful control of healthcare-associated, multi-resistant
ram-negative bacteria bacteria is relying on several com-
lementary control strategies. Clearly, there is no level
f antibiotic resistance where control measures are not
arranted any more. First, early detection of resistance
arriage may allow rapid contact isolation of identiﬁed car-
iers and improve the adequacy of antibiotic prophylaxis
nd treatment, especially in critically ill patients. Sev-
ral recent outbreak reports have shown the importance
f surveillance and screening cultures in order to prevent
ransmission and infection by multi-resistant Gram-negative
acteria in the critical care setting. Although the most
fﬁcient screening strategy depends on the local situation
nd type of resistance and is therefore still a matter of
ebate, most affected acute care hospitals should install
screening policy for patient groups at high risk of carriage
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of pan-resistant Acinetobacter spp or carbapenem-resistant
Klebsiella spp (e.g. roommates of newly identiﬁed carriers)
and apply speciﬁc preventive measures (contact isolation)
applied to identiﬁed carriers, especially in the critical
care setting. Second, eradicating carriage of multi-resistant
bacteria may reduce the rates of infection. However, no con-
trolled studies are available indicating that this approach
may work. Third, strict compliance with standard pre-
cautions and hand hygiene could prevent most cases of
cross-transmission, even without the need for recognition
of individual carriers of resistant microorganisms. Unfor-
tunately, many studies have shown that compliance of
healthcare workers with hand hygiene recommendations
remains low. Implementing alcohol-based hand rinses can
improve compliance and decrease cross-infection. Finally,
antibiotic selection pressure contributes to the increase in
prevalence of multi-resistant Gram-negative bacteria. Data
from several recently published studies suggest that restric-
tion of certain classes of antibiotics may decrease rates
of multi-resistant Gram-negative bacteria in the hospital
setting. Other well-designed investigations are needed to
conﬁrm that reduction in antimicrobial overuse has a favor-
able effect on infection rates caused by multi-resistant
Gram-negative bacteria.
doi:10.1016/j.ijid.2008.05.062
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Burden of Pertussis Worldwide: Strategies to Reinforce
Pertussis Control in Children, Adolescents, and Adults
K. Forsyth
Flinders Medical Centre and Flinders University, Adelaide,
Australia
Pertussis disease is a signiﬁcant cause of morbidity and
mortality amongst the unimmunised or insufﬁciently immu-
nised. Data on pertussis disease trends will be presented.
As for solutions, in spite of immunisation campaigns tar-
geted at parents of infants and children, there are still
major problems with. Strategies to reduce the burden of
pertussis disease include; universal adult immunisation,
selective immunisation of mothers and close family contacts
of newborns, selectiveimmunisation of health care work-
ers, selective immunisation of child care workers, universal
immunisation of adolescents, pre-school boosters at 4—6
years of. No single strategy is likely to be appropriate for
all. Data on pertussis disease and discussion around these
public health policy issues for the prevention of pertussis
will be discussed.
doi:10.1016/j.ijid.2008.05.063
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ertussis Control in Infants and Children
. Thisyakorn
Chulalongkorn Hospital, Bangkok, Thailand
n the prevaccine era, pertussis was one of the most com-
on childhood bacterial infections with more than half of
hildren becoming infected before school age. The disease
as one of the leading causes of infant death in the 19th
entury.
The introduction of whole-cell pertussis vaccine in
he 1940s and its subsequent widespread use globally
as resulted in a reduction in the incidence, morbidity
nd mortality of this disease. The whole-cell pertussis
accine was nevertheless associated with frequent local
nd systemic adverse reactions, occasionally some that
ere more severe such as febrile seizures or hypotonic-
yporesponsive episodes. The shift, in the 1990s, from
hole-cell pertussis vaccine to less reactogenic acellular
ertussis vaccine was associated with signiﬁcantly reduced
ates of vaccine-associated adverse events. In recent years,
cellular pertussis vaccine has been incorporated into
he immunization schedules of many developed countries,
radually replacing whole-cell pertussis vaccine. Dosing
chedules vary between countries. As it has become appar-
nt that the epidemiology of pertussis is gradually shifting
o the adolescent and adult age groups, many countries are
ugmenting their program of immunization by having intro-
uced, or are planning to introduce, an acellular pertussis
accine booster dose for use in children 6 years of age or in
he adolescent age group.
The use of combination vaccines with inclusion of acel-
ular pertussis vaccine in many countries has been proven
o be efﬁcacious and prevents children from undergoing an
xcessive number of injections. The individual components
ncluded in these combination vaccines can be adjusted
ccording to differences in the burden of disease in different
ountries.
oi:10.1016/j.ijid.2008.05.064
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he Role of Pertussis Booster Vaccinations in Adolescents
nd Adults
. Johnson
Sanoﬁ Pasteur, USA
n most developed countries, long-standing vaccination
rograms for infants and young children have led to substan-
ial decreases in pertussis disease since their introduction
n the 1940s. More recently, however, there has been a
esurgence of pertussis case reports, most notably among
dolescents and adults. Immunity from childhood pertus-
is vaccinations wanes after several years, but natural
oosting through repeated subclinical infection is now
ncommon; most adolescents and adults are again suscep-
ible to pertussis. Manifestations of pertussis in these age
roups are highly variable, ranging from mild symptoms
nlikely to prompt medical care through typical whoop-
ng cough. Complications are common and include sleep
